Actively Recruiting
Optimizing Antiviral Treatment with Paxlovid and Remdesivir in Immunocompromised Adults with Mild to Moderate COVID-19
Led by Calmy Alexandra · Updated on 2026-02-18
256
Participants Needed
4
Research Sites
11 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining two antiviral drugs, remdesivir and nirmatrelvirritonavir nirmatrelvirr, compared to using nirmatrelvirr alone. The study focuses on immunocompromised patients who have been diagnosed with asymptomatic or mild to moderate COVID-19. The goal is to see if the combination therapy or extending the duration of nirmatrelvirr treatment from 5 to 10 days can better reduce the presence of the virus in patients. Participants in this randomized, controlled trial receive one of four treatment plans nirmatrelvirr for 5 days, nirmatrelvirr for 10 days, nirmatrelvirr for 5 days plus a single dose of remdesivir, or nirmatrelvirr for 10 days plus a single dose of remdesivir. The oral nirmatrelvirr is given twice daily, and remdesivir is administered as a single intravenous dose. The study is conducted in several European countries and also includes an exploratory cohort for patients who are not randomized or choose not to participate. During the study, participants are monitored through regular viral testing using PCR from nasal swabs at multiple time points including day 5, day 10, and beyond. Clinical evaluations occur up to day 90 to track symptoms and outcomes. The primary measurement is the viral positivity rate at day 10. Researchers assess safety and viral response throughout the study, which aims to last until mid-2026.
CONDITIONS
Brief Title
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
Research Team
A
Alexandra Calmy, MD PhD
C
Chiara Fedeli, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here